{"id":"nonacog-alfa","rwe":[{"pmid":"40750723","year":"2025","title":"Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B.","finding":"","journal":"Clinical pharmacokinetics","studyType":"Clinical Study"},{"pmid":"38223989","year":"2024","title":"Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.","finding":"","journal":"European journal of haematology","studyType":"Clinical Study"},{"pmid":"37790744","year":"2023","title":"Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India.","finding":"","journal":"Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion","studyType":"Clinical Study"},{"pmid":"37065846","year":"2023","title":"Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.","finding":"","journal":"Research and practice in thrombosis and haemostasis","studyType":"Clinical Study"},{"pmid":"35420242","year":"2022","title":"Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.","finding":"","journal":"Haemophilia : the official journal of the World Federation of Hemophilia","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"Active","category":"status"},{"label":"Hereditary factor IX deficiency disease","category":"indication"},{"label":"Pfizer Ltd","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Dysgeusia","drugRate":"","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"","severity":"common","organSystem":""},{"effect":"Positive furin antibody test","drugRate":"19.2%","severity":"common","organSystem":""},{"effect":"Low-titer non-neutralizing antibodies against factor IX","drugRate":"21.2%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":["Recombinant factor IX (rFIX)","BeneFIX"],"company":"Pfizer Ltd","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=nonacog alfa","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:15:39.596837+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:15:56.001075+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:15:45.197747+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:15:39.664884+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nonacog alfa","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:15:45.424401+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor IX exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:15:47.339913+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108348/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:15:47.008887+00:00"}},"allNames":"recombinant coagulation factor ix","offLabel":[],"synonyms":["nonacog alfa","recombinant coagulation factor IX"],"timeline":[{"date":"1997-08-27","type":"positive","source":"DrugCentral","milestone":"EMA approval (Pfizer Ltd)"}],"aiSummary":"Recombinant Coagulation Factor IX is an exogenous protein used to treat conditions such as Hemophilia B and Hemophilia A, as well as severe bleeding episodes like intracranial hemorrhage. It works by replacing the deficient coagulation factor IX, which is involved in the blood clotting process, to prevent or control bleeding.","approvals":[{"date":"1997-08-27","orphan":false,"company":"Pfizer Ltd","regulator":"EMA"}],"brandName":"Recombinant Coagulation Factor Ix","ecosystem":[{"indication":"Hereditary factor IX deficiency disease","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Recombinant Coagulation Factor IX (nonacog alfa) is a glycoprotein produced through recombinant DNA technology, consisting of 415 amino acids and having a molecular weight of approximately 56 kDa. It functions as a cofactor for factor Xa in the intrinsic pathway of blood coagulation, facilitating the conversion of prothrombin to thrombin and subsequent clot formation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5163","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=nonacog%20alfa","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nonacog alfa","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T14:41:33.172190","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:15:56.001170+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"nonacog alfa","indications":{"approved":[{"name":"Hereditary factor IX deficiency disease","source":"DrugCentral","snomedId":41788008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04590950","phase":"","title":"Dosage and PD Study of Eftrenonacog-alfa","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-18","conditions":["Severe Haemophilia B"],"enrollment":15,"completionDate":"2020-03-31"},{"nctId":"NCT04398628","phase":"","title":"ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2020-09-30","conditions":["Hematologic Disorder","Bleeding Disorder","Connective Tissue Disorder","Hemophilia","Thrombosis","Von Willebrand Diseases","Thrombophilia","Rare Bleeding Disorder","Platelet Disorder","Factor IX Deficiency","Factor VIII Deficiency","Thalassemia","Sickle Cell Disease"],"enrollment":3000,"completionDate":"2035-12"},{"nctId":"NCT01154231","phase":"","title":"BeneFIX Drug Use Results Survey [All-Case Surveillance]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10-29","conditions":["Hemophilia B"],"enrollment":314,"completionDate":"2017-02-27"},{"nctId":"NCT02937831","phase":"","title":"RIXUBIS Drug Use-Result Survey (Japan)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-16","conditions":["Hemophilia B"],"enrollment":6,"completionDate":"2022-05-11"},{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":["Hemophilia B"],"enrollment":21,"completionDate":"2022-07-04"},{"nctId":"NCT03565237","phase":"PHASE4","title":"RIXUBIS PMS India (RIXUBIS PMS)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-12-07","conditions":["Hemophilia B"],"enrollment":25,"completionDate":"2021-08-11"},{"nctId":"NCT02053792","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-02-06","conditions":["Hemophilia B"],"enrollment":97,"completionDate":"2021-06-02"},{"nctId":"NCT04286412","phase":"PHASE4","title":"Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-02-10","conditions":["Hemophilia B"],"enrollment":25,"completionDate":"2020-09-24"},{"nctId":"NCT02234310","phase":"PHASE3","title":"Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2014-11-13","conditions":["Hemophilia B"],"enrollment":33,"completionDate":"2019-08-20"},{"nctId":"NCT03995784","phase":"PHASE2","title":"Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2019-06-18","conditions":["Hemophilia B"],"enrollment":6,"completionDate":"2020-04-30"},{"nctId":"NCT01286779","phase":"PHASE3","title":"BAX 326 (rFIX) Continuation Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-04-12","conditions":["Hemophilia B"],"enrollment":117,"completionDate":"2017-06-29"},{"nctId":"NCT01174446","phase":"PHASE3","title":"Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-07-29","conditions":["Hemophilia B"],"enrollment":86,"completionDate":"2012-05-03"},{"nctId":"NCT01488994","phase":"PHASE2,PHASE3","title":"BAX 326 Pediatric Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-20","conditions":["Hemophilia B"],"enrollment":23,"completionDate":"2013-05-14"},{"nctId":"NCT01507896","phase":"PHASE3","title":"BAX 326 Surgery Study in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-19","conditions":["Hemophilia B"],"enrollment":30,"completionDate":"2014-05-15"},{"nctId":"NCT02922231","phase":"","title":"Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-01-06","conditions":["Hemophilia B"],"enrollment":57,"completionDate":"2019-04-04"},{"nctId":"NCT02796222","phase":"","title":"Factor Product Utilization and Health Outcomes in Patients With Hemophilia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2016-04","conditions":["Hemophilia A, Congenital","Hemophilia B, Congenital"],"enrollment":61,"completionDate":"2021-04-26"},{"nctId":"NCT00768287","phase":"PHASE2,PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2009-01","conditions":["Hemophilia B"],"enrollment":77,"completionDate":"2016-12"},{"nctId":"NCT01271868","phase":"PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B","status":"TERMINATED","sponsor":"Medexus Pharma, Inc.","startDate":"2010-11","conditions":["Hemophilia B"],"enrollment":9,"completionDate":"2016-12"},{"nctId":"NCT01027364","phase":"PHASE3","title":"Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2009-12","conditions":["Severe Hemophilia B"],"enrollment":123,"completionDate":"2012-07"},{"nctId":"NCT01440946","phase":"PHASE3","title":"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2012-06","conditions":["Hemophilia B"],"enrollment":30,"completionDate":"2014-11"},{"nctId":"NCT00716716","phase":"PHASE1","title":"Phase I/IIa Study of FIXFc in Hemophilia B Patients","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2008-04","conditions":["Hemophilia B"],"enrollment":10,"completionDate":"2009-10"},{"nctId":"NCT04108260","phase":"PHASE4","title":"The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-04-21","conditions":["Hemophilia"],"enrollment":5,"completionDate":"2022-04"},{"nctId":"NCT03091751","phase":"PHASE2","title":"Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B","status":"COMPLETED","sponsor":"Grifols Biologicals, LLC","startDate":"2005-08","conditions":["Hemophilia B"],"enrollment":13,"completionDate":"2009-10"},{"nctId":"NCT02336178","phase":"PHASE4","title":"Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-01","conditions":["HEMOPHILIA B"],"enrollment":70,"completionDate":"2016-08"},{"nctId":"NCT00956345","phase":"PHASE1","title":"Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-08","conditions":["Congenital Bleeding Disorder","Haemophilia B"],"enrollment":18,"completionDate":"2010-07"},{"nctId":"NCT02048111","phase":"PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B","status":"WITHDRAWN","sponsor":"Cangene Corporation","startDate":"2014-03","conditions":["Hemophilia B"],"enrollment":0,"completionDate":"2015-11"},{"nctId":"NCT02213250","phase":"PHASE1","title":"An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-03","conditions":["Hemophilia B"],"enrollment":12,"completionDate":"2015-04"},{"nctId":"NCT01361126","phase":"PHASE1,PHASE2","title":"A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-07","conditions":["Hemophilia B"],"enrollment":17,"completionDate":"2012-07"},{"nctId":"NCT01496274","phase":"PHASE2,PHASE3","title":"A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-02","conditions":["Hemophilia B"],"enrollment":63,"completionDate":""},{"nctId":"NCT01335061","phase":"PHASE3","title":"Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":["Hemophilia B"],"enrollment":25,"completionDate":"2014-04"},{"nctId":"NCT00244114","phase":"","title":"Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-02","conditions":["Hemophilia B"],"enrollment":20,"completionDate":"2009-12"},{"nctId":"NCT01233440","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2010-10","conditions":["Hemophilia B"],"enrollment":25,"completionDate":"2011-07"},{"nctId":"NCT00364182","phase":"PHASE3","title":"Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-05","conditions":["Hemophilia B"],"enrollment":50,"completionDate":"2010-10"},{"nctId":"NCT00866606","phase":"PHASE3","title":"Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-02","conditions":["Hemophilia B"],"enrollment":35,"completionDate":"2009-12"},{"nctId":"NCT00167973","phase":"","title":"Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-01","conditions":["Hemophilia B"],"enrollment":218,"completionDate":"2009-06"},{"nctId":"NCT00581126","phase":"PHASE4","title":"Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2001-12","conditions":["Hemophilia B"],"enrollment":14,"completionDate":"2004-07"}],"_emaApprovals":[{"date":"1997-08-27","status":"Authorised","company":"Pfizer Ltd"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"22458","NDDF":"016050","VANDF":"4021022","RXNORM":"1300488","UMLSCUI":"C2826076","chemblId":"CHEMBL2108348","ChEMBL_ID":"CHEMBL2109205","DRUGBANK_ID":"DB00100","SNOMEDCT_US":"395860001"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Pfizer Ltd","relationship":"Original Developer"}],"publicationCount":27,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"originalDeveloper":"Pfizer Ltd","recentPublications":[{"date":"2025 Oct","pmid":"40750723","title":"Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B.","journal":"Clinical pharmacokinetics"},{"date":"2024 May","pmid":"38223989","title":"Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.","journal":"European journal of haematology"},{"date":"2023 Oct","pmid":"37790744","title":"Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India.","journal":"Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion"},{"date":"2023 Mar","pmid":"37065846","title":"Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.","journal":"Research and practice in thrombosis and haemostasis"},{"date":"2022 Jul","pmid":"35420242","title":"Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.","journal":"Haemophilia : the official journal of the World Federation of Hemophilia"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Pfizer Ltd","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"1997-08-27T00:00:00.000Z","mah":"Pfizer Ltd","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:15:56.001170+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}